# A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

> **NCT06129539** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Debiopharm International SA** · enrollment: 56 (estimated)

## Conditions studied

- Central Precocious Puberty

## Interventions

- **DRUG:** Debio 4326

## Key facts

- **NCT ID:** NCT06129539
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2026-10
- **Final completion:** 2028-02
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06129539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06129539, "A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT06129539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*